الانتقال إلى المحتوى الرئيسي
xMedica

NCT06628908ClinicalTrials.gov

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

المرحلة 3مطلوب 1,100 مشارك76 موقعاًدولة واحدة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 7 days after the recorded start)First posted 2024-10-08; recorded start 2024-10-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 92 other studies in this databaseCounted from the lead sponsor named in the record (Vertex Pharmaceuticals Incorporated)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 76 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,100 participants (target), run at 76 sites.

How this score is built
  • Enrolment30/40

    1,100 participants (target)

  • Site count22/25

    76 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 32 months

  • Sponsor scale7/10

    Vertex Pharmaceuticals Incorporated has led 90 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

الحالات

  • Diabetic Peripheral Neuropathic Pain

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years80 Years
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Key Inclusion Criteria: * Body weight greater than or equal to (≥) 45 kilogram (kg) * Body mass index (BMI) ≥18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2) * Diagnosis of diabetes mellitus type 1 or type 2 by glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN * Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period Key Exclusion Criteria: * More than 3 missing daily NPRS scores during the 7-day Baseline Period * Any sensory abnormality (excluding DPN) as pre-specified in the protocol Other protocol defined Inclusion/Exclusion criteria may apply.

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 3
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةQUADRUPLE (4)
التجنيدمطلوب 1,100 مشارك

الجهة الراعية والمتعاونون

  • Vertex Pharmaceuticals Incorporated الجهة الراعية

الأذرع والتدخلات

  • Suzetrigine (SUZ)EXPERIMENTAL

    Participants will be randomized to receive SUZ.

  • PregabalinACTIVE_COMPARATOR

    Participants will be randomized to receive Pregabalin.

  • PlaceboPLACEBO_COMPARATOR

    Participants will be randomized to receive placebo matched to SUZ and Pregabalin.

التدخلات

  • دواء Placebo (matched to Pregabalin)

    Placebo matched to Pregabalin for oral administration.

  • دواء Placebo (matched to SUZ)

    Placebo matched to SUZ for oral administration.

  • دواء Pregabalin

    Capsules for oral administration.

  • دواء Suzetrigine

    Tablets for oral administration.

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo

    الإطار الزمني From Baseline up to Week 12

  2. مقياس النتيجة الثانوي

    Change From Baseline in the Medical Outcomes Study 36-item Short-form Health Status (SF 36v2) Physical Component Summary (PCS) Score at Week 12 Compared to Placebo (pooled with data from Study VX24-548-111)

    الإطار الزمني From Baseline up to Week 12

  3. مقياس النتيجة الثانوي

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12 Compared to Pregabalin

    الإطار الزمني From Baseline up to Week 12

التواريخ

التواريخ
تاريخ البدء1 أكتوبر 2024 (فعلي)
الإتمام الأولي31 مايو 2027 (تقديري)
الإتمام31 مايو 2027 (تقديري)
أول نشر8 أكتوبر 2024 (فعلي)
آخر تحديث15 يونيو 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةيونيو 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

59 موقعاً قيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Albany Medical CollegeAlbanyNew Yorkمكتمل
Velocity Clinical Research - AlbuquerqueAlbuquerqueNew Mexicoقيد التجنيد
Synexus Clinical Research- AndersonAndersonSouth Carolinaمكتمل
Pinnacle Research Group, LLCAnnistonAlabamaقيد التجنيد
Velocity Clinical Research - Baton RougeBaton RougeLouisianaقيد التجنيد
Velocity Clinical Research - ClevelandBeachwoodOhioقيد التجنيد
Northwest Clinical Research Center (NWCRC)BellevueWashingtonقيد التجنيد
Synexus Clinical Research - BirminghamBirminghamAlabamaمكتمل
Mass General Brigham - Brigham and Women's Hospital - Main CampusBostonMassachusettsقيد التجنيد
Swift Clinical OpCo, IncBrooklynNew Yorkقيد التجنيد
Clinical Trials of South Carolina - Berkeley - CharlestonCharlestonSouth Carolinaقيد التجنيد
M3 Wake Research - CharlestonCharlestonSouth Carolinaقيد التجنيد
Feinberg School of Medicine - AnesthesiologyChicagoIllinoisقيد التجنيد
Synexus Clinical Research - CincinnatiCincinnatiOhioمكتمل
Tandem Clinical Research- CovingtonCovingtonLouisianaقيد التجنيد
Synexus Clinical Research - Dallas (DFW) (DRS)DallasTexasمكتمل
Zenos Clinical ResearchDallasTexasقيد التجنيد
AMR Daphne, ALDaphneAlabamaمكتمل
META Medical Research InstituteDaytonOhioقيد التجنيد
Accel Research - DelandDeLandFloridaقيد التجنيد
Accel Research - DecaturDecaturGeorgiaقيد التجنيد
AMR-MiamiDoralFloridaقيد التجنيد
Velocity Clinical Research - ProvidenceEast GreenwichRhode Islandقيد التجنيد
Velocity Clinical Research - SyracuseEast SyracuseNew Yorkقيد التجنيد
Velocity Clinical Research - DenverEnglewoodColoradoقيد التجنيد
Synexus Clinical Research - EvansvilleEvansvilleIndianaمكتمل
Healthcare Research Network - Flossmoor ILFlossmoorIllinoisقيد التجنيد
AMR Fort Myers (The Clinical Study Center)Fort MyersFloridaقيد التجنيد
Neuro-Pain Medical CenterFresnoCaliforniaقيد التجنيد
Velocity Clinical Research - Grants PassGrants PassOregonمكتمل
Velocity Clinical Research - Hallandale BeachHallandaleFloridaقيد التجنيد
Healthcare Research Network - Hazelwood MOHazelwoodMissouriقيد التجنيد
CNS Healthcare - JacksonvilleJacksonvilleFloridaقيد التجنيد
AMR Kansas CityKansas CityMissouriقيد التجنيد
Accel Research - St. Petersburg-LargoLargoFloridaقيد التجنيد
Synexus Clinical Research - Las VegasLas VegasNevadaمكتمل
AMR LexingtonLexingtonKentuckyقيد التجنيد
Long Beach Research InstituteLong BeachCaliforniaقيد التجنيد
Angel City Research, IncLos AngelesCaliforniaقيد التجنيد
Accel Research - MaitlandMaitlandFloridaمكتمل
HRI - Hassman Research InstituteMarltonNew Jerseyمكتمل
Velocity Clinical Research - MedfordMedfordOregonقيد التجنيد
Suburban Research Associates - MediaMediaPennsylvaniaقيد التجنيد
Velocity Clinical Research - BoiseMeridianIdahoقيد التجنيد
Suncoast Research Associates - MiamiMiamiFloridaقيد التجنيد
3Sync Research - Miami LakesMiami LakesFloridaقيد التجنيد
West Clinical ResearchMorehead CityNorth Carolinaقيد التجنيد
AMR Nashville, TNNashvilleTennesseeمكتمل
Suncoast Clinical Research - New Port RicheyNew Port RicheyFloridaقيد التجنيد
Columbia Presbyterian - The Neurological Institute of New YorkNew YorkNew Yorkقيد التجنيد

يُدرَج 26 موقعاً إضافياً في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.

يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.